Autoimmune therapy - Cartesian Therapeutics
Alternative Names: ImmTORTM PBCLatest Information Update: 28 Apr 2025
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Hepatoprotectants
- Mechanism of Action Dendritic cell stimulants; Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Primary biliary cirrhosis